Publications by authors named "MaryBeth Gonyo"
Article Synopsis
- About 20-25% of hormone-receptor positive breast cancer patients develop resistance to endocrine therapy, often linked to HER family receptor upregulation.
- A phase II clinical trial studied the effects of a 4-week neoadjuvant endocrine therapy on early-stage HR+/HER2-negative breast cancer patients, focusing on changes in HER1-4 protein levels.
- The results showed significant HER2 upregulation in almost half of the patients post-therapy, indicating it as a potential escape mechanism, although no major tumor size reduction was observed.
